{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2v1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Strong","contributions":[{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10106","date":"2024-04-23T20:11:05.772Z","role":"Publisher"},{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10106","date":"2023-09-21T16:00:00.000Z","role":"Approver"}],"curationReasons":{"id":"cg:ErrorClarification"},"evidence":[{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:b316c282-90ea-475f-b30a-429b3f8db0d1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b316c282-90ea-475f-b30a-429b3f8db0d1","type":"Proband","allele":[{"id":"cggv:e8c1f340-c4f5-4b0f-9914-e6b0b35e7a12","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1570C>T (p.Arg524Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115751"}},{"id":"cggv:dd32cb35-7981-451a-aea2-a018d0ac03f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.771T>A (p.Phe257Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115749"}}],"detectionMethod":"GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001399","obo:HP_0001394"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"UnknownEthnicity","variant":[{"id":"cggv:31b5f3ae-48c2-4c2b-b77b-920604b963e8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:dd32cb35-7981-451a-aea2-a018d0ac03f0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/8613547","type":"dc:BibliographicResource","dc:abstract":"Glycogen storage disease type IV (GSD-IV) is an autosomal recessive disease resulting from deficient glycogen-branching enzyme (GBE) activity. The classic and most common form is progressive liver cirrhosis and failure leading to either liver transplantation or death by 5 yr of age. However, the liver disease is not always progressive. In addition, a neuromuscular type of the disease has been reported. The molecular basis of GSD-IV is not known, nor is there a known reason for the clinical variability. We studied the GBE gene in patients with various presentations of GSD-IV. Three point mutations in the GBE gene were found in two patients with the classical presentation: R515C, F257L, and R524X. Transient expression experiments showed that these mutations inactivated GBE activity. Two point mutations, L224P and Y329S, were detected in two separate alleles of a patient with the nonprogressive hepatic form. The L224P resulted in complete loss of GBE activity, whereas the Y329S resulted in loss of approximately 50% of GBE activity. The Y329S allele was also detected in another patient with the nonprogressive form of GSD-IV but not in 35 unrelated controls or in patients with the more severe forms of GSD-IV. A 210-bp deletion from nucleotide 873 to 1082 of the GBE cDNA was detected in a patient with the fatal neonatal neuromuscular presentation. This deletion, representing the loss of one full exon, was caused by a 3' acceptor splicing site mutation (ag to aa). The deletion abolished GBE activity. Our studies indicate that the three different forms of GSD-IV were caused by mutations in the same GBE gene. The data also suggest that the significant retention of GBE activity in the Y329S allele may be a reason for the mild disease. Further study of genotype/phenotype correlations may yield useful information in predicting the clinical outcomes.","dc:creator":"Bao Y","dc:date":"1996","dc:title":"Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene."}},{"id":"cggv:0020fbaa-33d2-478e-84d8-976ed0b46173_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e8c1f340-c4f5-4b0f-9914-e6b0b35e7a12"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"}],"rdfs:label":"Patient 4"},{"id":"cggv:31b5f3ae-48c2-4c2b-b77b-920604b963e8","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:31b5f3ae-48c2-4c2b-b77b-920604b963e8_variant_evidence_item"},{"id":"cggv:31b5f3ae-48c2-4c2b-b77b-920604b963e8_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Approximately 25% GBE activity when transfected into COS-7 cells "}],"strengthScore":0.1,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence."},{"id":"cggv:0020fbaa-33d2-478e-84d8-976ed0b46173","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0020fbaa-33d2-478e-84d8-976ed0b46173_variant_evidence_item"},{"id":"cggv:0020fbaa-33d2-478e-84d8-976ed0b46173_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Abolished GBE activity when transfected into COS-7 cells "}],"strengthScore":1.5,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:06921186-ff37-4d26-aa34-1259652c303a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:06921186-ff37-4d26-aa34-1259652c303a","type":"Proband","allele":{"id":"cggv:81365c77-cdbf-4374-88ec-c207964243ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1468del (p.Leu490TrpfsTer5)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499641"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001558","obo:HP_0100299","obo:HP_0001252","obo:HP_0001561","obo:HP_0001315"],"sex":"UnknownEthnicity","variant":{"id":"cggv:5ba4da86-bf98-4a6a-b76e-28154a665e9c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:81365c77-cdbf-4374-88ec-c207964243ee"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15520786","type":"dc:BibliographicResource","dc:abstract":"The fatal neonatal form of type IV glycogen storage disease (GSD IV) was diagnosed on light and electron microscopy and by analysis of GBE1 , the gene encoding glycogen branching enzyme. We report two novel truncating mutations, as well as the first genomic mutational analysis of GBE1 using denaturing high performance liquid chromatography.","dc:creator":"Janecke AR","dc:date":"2004","dc:title":"Neonatal type IV glycogen storage disease associated with \"null\" mutations in glycogen branching enzyme 1."}},"rdfs:label":"Patient "},{"id":"cggv:5ba4da86-bf98-4a6a-b76e-28154a665e9c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:5ba4da86-bf98-4a6a-b76e-28154a665e9c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:7abbb198-f157-4771-9f08-7a03fba15bc1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7abbb198-f157-4771-9f08-7a03fba15bc1","type":"Proband","allele":{"id":"cggv:113c0fdc-0303-4c8f-8600-4de815feefbe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1634A>G (p.His545Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115756"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001561","obo:HP_0001511","obo:HP_0001371"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Female","variant":{"id":"cggv:4ab330fa-2c17-4e8d-b04b-2153042fcad5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:113c0fdc-0303-4c8f-8600-4de815feefbe"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/10545044","type":"dc:BibliographicResource","dc:abstract":"We have identified a novel missense mutation in the gene for glycogen branching enzyme (GBE 1) in a 16-month-old infant with a combination of hepatic and muscular features, an atypical clinical presentation of glycogenosis type IV (GSD IV). The patient was heterozygous for a G-to-A substitution at codon 524 (R524Q), changing an encoded arginine (CGA) to glutamine (CAA), while the GBE1 gene on the other allele was not expressed. This case broadens the spectrum of mutations in patients with GSD IV and confirms the clinical and molecular heterogeneity of this disease.","dc:creator":"Bruno C","dc:date":"1999","dc:title":"A novel missense mutation in the glycogen branching enzyme gene in a child with myopathy and hepatopathy."}},"rdfs:label":"Patient 2,3 (sibs)"},{"id":"cggv:4ab330fa-2c17-4e8d-b04b-2153042fcad5","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:4ab330fa-2c17-4e8d-b04b-2153042fcad5_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:6731e101-a671-45f4-bedd-5bae53363fcd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:6731e101-a671-45f4-bedd-5bae53363fcd","type":"Proband","allele":{"id":"cggv:46efa815-e6ad-417a-ae43-584fd06bf24e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.783-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115742"}},"detectionMethod":"GBE1 gene sequencing","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001558","obo:HP_0001315","obo:HP_0001635","obo:HP_0001252","obo:HP_0001561"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"UnknownEthnicity","variant":{"id":"cggv:c0664c19-a076-46ce-995e-d754a400bf2d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:46efa815-e6ad-417a-ae43-584fd06bf24e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"},"rdfs:label":"Patient 1"},{"id":"cggv:c0664c19-a076-46ce-995e-d754a400bf2d","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:c0664c19-a076-46ce-995e-d754a400bf2d_variant_evidence_item"},{"id":"cggv:c0664c19-a076-46ce-995e-d754a400bf2d_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Transfected variant into COS-7 cells and showed abolished enzyme activity"}],"strengthScore":0.75,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence.  We are counting homozygous variants as one variant for a total score of 1.5"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c92e037d-63be-4a9a-bf6a-d28c6579d322_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c92e037d-63be-4a9a-bf6a-d28c6579d322","type":"Proband","allele":{"id":"cggv:b4df613e-85ed-4683-9d90-37bb2c31f1f1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.143+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115755"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001371","obo:HP_0001252","obo:HP_0001789"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Female","variant":{"id":"cggv:4d59ed7e-4338-426b-89f2-365b1dda2665_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b4df613e-85ed-4683-9d90-37bb2c31f1f1"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"},"rdfs:label":"Patient 1"},{"id":"cggv:4d59ed7e-4338-426b-89f2-365b1dda2665","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:4d59ed7e-4338-426b-89f2-365b1dda2665_variant_evidence_item"}],"strengthScore":0.75,"dc:description":"We are counting homozygous variants as one variant for a total score of 1.5"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:09bf0160-8709-42fa-ac40-b94c2d2151c6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:09bf0160-8709-42fa-ac40-b94c2d2151c6","type":"Proband","allele":[{"id":"cggv:a392f6ce-96e3-4794-9ac6-5e1535c709b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1239del (p.Asp413GlufsTer23)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499726"}},{"id":"cggv:81365c77-cdbf-4374-88ec-c207964243ee"}],"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001252","obo:HP_0001561","obo:HP_0001315"],"previousTesting":true,"previousTestingDescription":"Reduced GBE activity in muscle homogenate","sex":"Female","variant":[{"id":"cggv:94a421f4-dfe9-4bb0-9c04-d1528a2d4f1b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:81365c77-cdbf-4374-88ec-c207964243ee"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15019703","type":"dc:BibliographicResource","dc:abstract":"Glycogen storage disease type IV or Andersen disease is an autosomal recessive disorder due to deficiency of glycogen branching enzyme. Typically, glycogen storage disease type IV presents with rapidly progressive liver cirrhosis and death in childhood. Variants include a cardiopathic form of childhood, a relatively benign myopathic form of young adults, and a late-onset neurodegenerative disorder (adult polyglucosan body disease). A severe neuromuscular variant resembling Werdnig-Hoffmann disease has also been described in two patients. The objective was to describe two additional infants with the neuromuscular variant and novel mutations in the GBE1 gene. Branching enzyme assay, Western blot, RT-PCR and sequencing were performed in muscle biopsies from both patients. The cDNA of patient 1 was subcloned and sequenced to define the mutations. Muscle biopsies showed accumulation of periodic acid Schiff-positive, diastase-resistant storage material in both patients and increased lysosomal enzyme activity in patient 1. Branching enzyme activity in muscle was negligible in both patients, and Western blot showed decreased branching enzyme protein. Patient 1 had two single base pair deletions, one in exon 10 (1238delT) and the other in exon 12 (1467delC), and each parent was heterozygous for one of the deletions. Patient 2 had a large homozygous deletion that spanned 627 bp and included exons 8-12. Patient 1, who died at 41 days, had neurophysiological and neuropathological features of Spinal Muscular Atrophy. Patient 2, who died at 5(1/2) weeks, had a predominantly myopathic process. The infantile neuromuscular form of glycogen storage disease type IV is considered extremely rare, but our encountering two patients in close succession suggests that the disease may be underdiagnosed.","dc:creator":"Tay SK","dc:date":"2004","dc:title":"Fatal infantile neuromuscular presentation of glycogen storage disease type IV."}},{"id":"cggv:4955bdae-a856-46be-a7b4-80e6366ec203_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a392f6ce-96e3-4794-9ac6-5e1535c709b0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/15019703"}],"rdfs:label":"Patient 1"},{"id":"cggv:4955bdae-a856-46be-a7b4-80e6366ec203","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:4955bdae-a856-46be-a7b4-80e6366ec203_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:94a421f4-dfe9-4bb0-9c04-d1528a2d4f1b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:94a421f4-dfe9-4bb0-9c04-d1528a2d4f1b_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9b23e9f6-3f70-4cc9-90c8-1a093fbb4993_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9b23e9f6-3f70-4cc9-90c8-1a093fbb4993","type":"Proband","allele":{"id":"cggv:3b3a2cf0-a50e-43b9-84b9-8b5ebd6b94af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1643G>A (p.Trp548Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115767"}},"detectionMethod":"Whole GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001558","obo:HP_0100299","obo:HP_0001252","obo:HP_0001561"],"sex":"Female","variant":{"id":"cggv:d47a7c3d-cf5e-466b-9500-197c0dcd5f49_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:3b3a2cf0-a50e-43b9-84b9-8b5ebd6b94af"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17662246","type":"dc:BibliographicResource","dc:abstract":"Glycogen branching enzyme deficiency (glycogen storage disease type IV, GSD-IV) is a rare autosomal recessive disorder of the glycogen synthesis with high mortality. Two female newborns showed severe hypotonia at birth and both died of cardiorespiratory failure, at 4 and 12 weeks, respectively. In both patients, muscle biopsies showed deposits of PAS-positive diastase-resistant material and biochemical analysis in cultured fibroblasts showed markedly reduced glycogen branching enzyme activity. Direct sequencing of GBE1 gene revealed that patient 1 was homozygous for a novel c.691+5 g>c in intron 5 (IVS5+5 g>c). RT-PCR analysis of GBE1 transcripts from fibroblasts cDNA showed that this mutation produce aberrant splicing. Patient 2 was homozygous for a novel c.1643G>A mutation leading to a stop at codon 548 in exon 13 (p.W548X). These data underscore that in GSD-IV a severe phenotype correlates with null mutations, and indicate that RNA analysis is necessary to characterize functional consequences of intronic mutations.","dc:creator":"Assereto S","dc:date":"2007","dc:title":"Null mutations and lethal congenital form of glycogen storage disease type IV."}},"rdfs:label":"Patient 2"},{"id":"cggv:d47a7c3d-cf5e-466b-9500-197c0dcd5f49","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d47a7c3d-cf5e-466b-9500-197c0dcd5f49_variant_evidence_item"},{"id":"cggv:d47a7c3d-cf5e-466b-9500-197c0dcd5f49_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Western blot showing absence of normal protein.  Reduced GBE activity in patient fibroblasts.  "}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f2d0e6af-cfd6-46c7-8a6b-fab87176e5d5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f2d0e6af-cfd6-46c7-8a6b-fab87176e5d5","type":"Proband","allele":{"id":"cggv:e5ee7704-0552-4952-9e96-81497c2abdab","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.986A>C (p.Tyr329Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115743"}},"detectionMethod":"GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001394","obo:HP_0001395"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"UnknownEthnicity","variant":{"id":"cggv:044a8c2b-0d31-4851-bd2c-bdf13752d681_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e5ee7704-0552-4952-9e96-81497c2abdab"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"},"rdfs:label":"Patient 5"},{"id":"cggv:044a8c2b-0d31-4851-bd2c-bdf13752d681","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:044a8c2b-0d31-4851-bd2c-bdf13752d681_variant_evidence_item"},{"id":"cggv:044a8c2b-0d31-4851-bd2c-bdf13752d681_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Approximately 50% loss of GBE activity when transfected into COS-7 cells "}],"strengthScore":0,"dc:description":"Previously counted this variant in a prior patient who had this variant in trans with another variant. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:b4af79e9-1b89-4f00-b9aa-7b371635efb6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:b4af79e9-1b89-4f00-b9aa-7b371635efb6","type":"Proband","allele":[{"id":"cggv:e5ee7704-0552-4952-9e96-81497c2abdab"},{"id":"cggv:9a068c7a-8a3c-4c89-b1e3-f3d7c2f2dd77","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.671T>C (p.Leu224Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115745"}}],"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001395","obo:HP_0002240","obo:HP_0002910"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity. ","sex":"Female","variant":[{"id":"cggv:6439b033-ce7d-467e-a425-a9080f2172de_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e5ee7704-0552-4952-9e96-81497c2abdab"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"},{"id":"cggv:3abda14e-f163-443a-89ae-009ec21dd835_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9a068c7a-8a3c-4c89-b1e3-f3d7c2f2dd77"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"}],"rdfs:label":"Patient 2"},{"id":"cggv:6439b033-ce7d-467e-a425-a9080f2172de","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:6439b033-ce7d-467e-a425-a9080f2172de_variant_evidence_item"},{"id":"cggv:6439b033-ce7d-467e-a425-a9080f2172de_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"50% loss of GBE activity in COS-7 cells "}],"strengthScore":0.1,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence."},{"id":"cggv:3abda14e-f163-443a-89ae-009ec21dd835","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3abda14e-f163-443a-89ae-009ec21dd835_variant_evidence_item"},{"id":"cggv:3abda14e-f163-443a-89ae-009ec21dd835_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Abolished GBE activity in COS-7 cells"}],"strengthScore":0.1,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8e7bf14f-455b-412d-a9fa-90be9dc67e61_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8e7bf14f-455b-412d-a9fa-90be9dc67e61","type":"Proband","allele":{"id":"cggv:0c32b0f8-2935-4641-a417-67af5b19d670","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1543C>T (p.Arg515Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115747"}},"detectionMethod":"GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001399","obo:HP_0001394"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"UnknownEthnicity","variant":{"id":"cggv:afbd0ba1-418d-43ed-9132-364f8bd273a2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:0c32b0f8-2935-4641-a417-67af5b19d670"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547"},"rdfs:label":"Patient 3 "},{"id":"cggv:afbd0ba1-418d-43ed-9132-364f8bd273a2","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:afbd0ba1-418d-43ed-9132-364f8bd273a2_variant_evidence_item"},{"id":"cggv:afbd0ba1-418d-43ed-9132-364f8bd273a2_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Approximately 25% GBE enzyme activity when tranfected into COS-7 cells "}],"strengthScore":0.1,"dc:description":"We are not using functional data to upgrade the variant because we are counting functional data in experimental evidence.  "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:26af16a2-0333-450f-ab56-749b08caab3b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:26af16a2-0333-450f-ab56-749b08caab3b","type":"Proband","allele":[{"id":"cggv:fb29ac73-51d9-44de-9793-a662e14ff433","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.895G>T (p.Gly299Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499838"}},{"id":"cggv:da4f31c5-4330-4c2c-aeaf-61543b81b1af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1471G>C (p.Ala491Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353684874"}}],"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000476","obo:HP_0001371","obo:HP_0100299"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Male","variant":[{"id":"cggv:3b45de55-7256-4708-b502-cfe1ce491983_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:da4f31c5-4330-4c2c-aeaf-61543b81b1af"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16278887","type":"dc:BibliographicResource","dc:abstract":"We report on a family of three consecutive fetuses affected by type IV glycogen storage disease (GSD IV). In all cases, cervical cystic hygroma was observed on the 12-week-ultrasound examination. During the second trimester, fetal hydrops developed in the first pregnancy whereas fetal akinesia appeared in the second pregnancy. The diagnosis was suggested by microscopic examination of fetal tissues showing characteristic inclusions exclusively in striated fibers, then confirmed by enzymatic studies on frozen muscle. Antenatal diagnosis was performed on the third and fourth pregnancies: cervical cystic hygroma and low glycogen branching enzyme (GBE) activity on chorionic villi sample (CVS) were detected in the third pregnancy whereas ultrasound findings were normal and GBE activity within normal range on CVS in the fourth pregnancy. Molecular analysis showed that the mother was heterozygous for a c.1471G > C mutation in exon 12, leading to the replacement of an alanine by a tyrosine at codon 491 (p.A491T); the father was heterozygous for a c.895G > T mutation in exon 7, leading to the creation of a stop codon at position 299 (p.G299X). GSD IV has to be considered in a context of cervical cystic hygroma with normal karyotype, particularly when second trimester hydrops or akinesia develop. Enzymatic analysis of GBE must be performed on CVS or amniotic cells to confirm the diagnosis. Characteristic intracellular inclusions are specific to the disease and should be recognized, even in macerated tissues after fetal death. Genetic analysis of the GBE gene may help to shed some light on the puzzling diversity of GSD IV phenotypes.","dc:creator":"L'herminÃ©-Coulomb A","dc:date":"2005","dc:title":"Fetal type IV glycogen storage disease: clinical, enzymatic, and genetic data of a pure muscular form with variable and early antenatal manifestations in the same family."}},{"id":"cggv:44e18ae0-f885-4ef6-a791-4093ec949bcf_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fb29ac73-51d9-44de-9793-a662e14ff433"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16278887"}],"rdfs:label":"Patient "},{"id":"cggv:3b45de55-7256-4708-b502-cfe1ce491983","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:3b45de55-7256-4708-b502-cfe1ce491983_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:44e18ae0-f885-4ef6-a791-4093ec949bcf","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:44e18ae0-f885-4ef6-a791-4093ec949bcf_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e47933e7-1257-42a7-ae98-31b0f3359e80_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e47933e7-1257-42a7-ae98-31b0f3359e80","type":"Proband","allele":[{"id":"cggv:16947eed-b984-49e9-a4b9-4a4b37827b24","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1571G>A (p.Arg524Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115753"}},{"id":"cggv:b70f7d26-0bce-4761-83ee-9b18e4b71d43","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.38dup (p.Asp13GlufsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184955"}}],"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001399","obo:HP_0001252","obo:HP_0001371"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Male","variant":[{"id":"cggv:7e14f5c3-9225-4403-a6b2-9c30c349694f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b70f7d26-0bce-4761-83ee-9b18e4b71d43"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"},{"id":"cggv:a516272c-5215-44ea-b248-9b3ec6c6abed_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:16947eed-b984-49e9-a4b9-4a4b37827b24"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"}],"rdfs:label":"Patient 8"},{"id":"cggv:7e14f5c3-9225-4403-a6b2-9c30c349694f","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:7e14f5c3-9225-4403-a6b2-9c30c349694f_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:a516272c-5215-44ea-b248-9b3ec6c6abed","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a516272c-5215-44ea-b248-9b3ec6c6abed_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9ccb9330-cade-4e8e-98b0-05d347cc5725_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:9ccb9330-cade-4e8e-98b0-05d347cc5725","type":"Proband","allele":[{"id":"cggv:1cec99f8-db45-4f3e-9e95-7930aff29adc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.728A>G (p.His243Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353688116"}},{"id":"cggv:87d62c65-2be6-4aa8-a1f3-69447724b39c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1909C>T (p.Arg637Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2499528"}}],"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001252","obo:HP_0001558"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Female","variant":[{"id":"cggv:7d608f71-8162-4c60-ad9e-517f00816c81_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:87d62c65-2be6-4aa8-a1f3-69447724b39c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"},{"id":"cggv:e15ffd7d-8135-4626-816e-158d31f409c9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1cec99f8-db45-4f3e-9e95-7930aff29adc"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"}],"rdfs:label":"Patient 6"},{"id":"cggv:e15ffd7d-8135-4626-816e-158d31f409c9","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e15ffd7d-8135-4626-816e-158d31f409c9_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:7d608f71-8162-4c60-ad9e-517f00816c81","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:7d608f71-8162-4c60-ad9e-517f00816c81_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:d94aac90-4b42-4a84-a7e4-9f8c76bd78ae_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:d94aac90-4b42-4a84-a7e4-9f8c76bd78ae","type":"Proband","allele":{"id":"cggv:4d6eccf0-aec3-475c-a8c7-e997a05b7cf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.288del (p.Gly97GlufsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16040929"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001558","obo:HP_0001561","obo:HP_0001635","obo:HP_0001252","obo:HP_0001315"],"sex":"Female","variant":{"id":"cggv:b1ed71bb-820a-4272-8c24-6db0454872fb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4d6eccf0-aec3-475c-a8c7-e997a05b7cf0"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/12913206","type":"dc:BibliographicResource","dc:abstract":"We report of an infant with neonatal glycogen storage disease type IV (GSD IV) who was examined for severe hypotonia and cardiomyopathy. On the muscle biopsy there were many fibers with diastase-resistant polyglucosan bodies. Glycogen branching enzyme (GBE1) activity in the muscle was markedly reduced. The infant had a homozygous single nucleotide deletion in the open reading frame of GBE1 gene.","dc:creator":"Nambu M","dc:date":"2003","dc:title":"A neonatal form of glycogen storage disease type IV."}},"rdfs:label":"Patient "},{"id":"cggv:b1ed71bb-820a-4272-8c24-6db0454872fb","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:b1ed71bb-820a-4272-8c24-6db0454872fb_variant_evidence_item"},{"id":"cggv:b1ed71bb-820a-4272-8c24-6db0454872fb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Deficient GBE activity"}],"strengthScore":0.75,"dc:description":"We are counting homozygous variants as one variant for a total score of 1.5"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:228355b2-250f-4be2-a495-48031af37766_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:228355b2-250f-4be2-a495-48031af37766","type":"Proband","allele":{"id":"cggv:318b6670-680d-4fee-87c9-7b066f043c67","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1774G>T (p.Glu592Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115758"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001252","obo:HP_0001558","obo:HP_0001561"],"previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Male","variant":{"id":"cggv:d078d8a4-45cb-44f6-a03f-c2f7c10b8e57_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:318b6670-680d-4fee-87c9-7b066f043c67"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"},"rdfs:label":"Patients 4,5 (sibs)"},{"id":"cggv:d078d8a4-45cb-44f6-a03f-c2f7c10b8e57","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:d078d8a4-45cb-44f6-a03f-c2f7c10b8e57_variant_evidence_item"}],"strengthScore":3,"dc:description":"This variant was seen in trans with a deletion of exons 4-6.  I do not have more information on the breakpoints, so I am adding points for the deletion here. "}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c06fa592-2d9a-4c79-b624-a2f91491c8cc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c06fa592-2d9a-4c79-b624-a2f91491c8cc","type":"Proband","allele":{"id":"cggv:c2a0a003-3e80-45d0-814e-6c6164f1df92","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.691+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115766"}},"detectionMethod":"Full GBE1 gene sequencing ","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001252","obo:HP_0001558","obo:HP_0001315","obo:HP_0001561","obo:HP_0031334"],"previousTesting":false,"sex":"Female","variant":{"id":"cggv:410aa094-65f1-45b2-bad0-067c57d09bbf_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c2a0a003-3e80-45d0-814e-6c6164f1df92"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17662246"},"rdfs:label":"Patient 1"},{"id":"cggv:410aa094-65f1-45b2-bad0-067c57d09bbf","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:410aa094-65f1-45b2-bad0-067c57d09bbf_variant_evidence_item"},{"id":"cggv:410aa094-65f1-45b2-bad0-067c57d09bbf_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Western blot - no normal protein present.  Reduced GBE enzyme function in patient fibroblasts. "}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:11d6e657-4f7c-44c1-beed-b87d4b9757d4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:11d6e657-4f7c-44c1-beed-b87d4b9757d4","type":"Proband","allele":{"id":"cggv:013ef280-1222-4ebc-879a-1bc243d5b252","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000158.4(GBE1):c.1883A>G (p.His628Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115760"}},"detectionMethod":"Full GBE1 gene sequencing","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0001252","previousTesting":true,"previousTestingDescription":"Enzymatically confirmed diagnosis of GSD due to deficient branching enzyme activity.","sex":"Male","variant":{"id":"cggv:b2b1662c-7794-41c1-aa5f-962036da2230_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:013ef280-1222-4ebc-879a-1bc243d5b252"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044"},"rdfs:label":"Patient 7"},{"id":"cggv:b2b1662c-7794-41c1-aa5f-962036da2230","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:b2b1662c-7794-41c1-aa5f-962036da2230_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:634a9034-460d-4290-8846-977c354b919c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:726fed92-3861-4ec5-a592-c4cc57571011","type":"Finding","demonstrates":{"id":"cg:GeneExpressionB"},"dc:description":"Reduced GBE1 mRNA in cells of affected patients.  ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613547","rdfs:label":"Northern blot "}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:b166fb02-f892-433a-96b6-6d663e24ad54","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:7ce2ff89-9691-4d14-8089-3bc2e6006814","type":"FunctionalAlteration","dc:description":"Undetectable GBE enzyme activity in affected patients.  Reduced activity ~50% in unaffected carrier relatives. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/9851430","type":"dc:BibliographicResource","dc:abstract":"Adult polyglucosan body disease (APBD) is a late-onset, slowly progressive disorder of the nervous system caused by glycogen branching enzyme (GBE) deficiency in a subgroup of patients of Ashkenazi Jewish origin. Similar biochemical finding is shared by glycogen storage disease type IV (GSD IV) that, in contrast to APBD, is an early childhood disorder with primarily systemic manifestations. Recently, the GBE cDNA was cloned and several mutations were characterized in different clinical forms of GSD IV. To examine whether mutations in the GBE gene account for APBD, we studied 7 patients from five Jewish families of Ashkenazi ancestry. The diagnosis was based on the typical clinical and pathological findings, and supported by reduced GBE activity. We found that the clinical and biochemical APBD phenotype in all five families cosegregated with the Tyr329Ser mutation, not detected in 140 controls. As this mutation was previously identified in a nonprogressive form of GSD IV and was shown in expression studies to result in a significant residual GBE activity, present findings explain the late onset and slowly progressive course of APBD in our patients. We conclude that APBD represents an allelic variant of GSD IV, but the reason for the difference in primary tissue involvement must be established.","dc:creator":"Lossos A","dc:date":"1998","dc:title":"Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene."},"rdfs:label":"GBE enzyme activity assay "}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"cggv:c3e16181-e771-44d6-a80e-b4ecadd2b94c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:6ccdd2ff-a02a-458a-96d0-dbca90ac5207","type":"FunctionalAlteration","dc:description":"Residual GBE enzyme activity measured through validated assay ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10545044","rdfs:label":"GBE enzyme activity in fibroblasts "}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:1278ea08-50d8-4ada-90be-126baa8ebfe6","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:aa43a434-b350-4c1a-9091-fe09f1c3fc44","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Both cats and humans are at risk for stillbirth or IUFD.  Both experience muscle weakness and cardiomyopathy. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17257876","type":"dc:BibliographicResource","dc:abstract":"Deficiency of glycogen branching enzyme (GBE) activity causes glycogen storage disease type IV (GSD IV), an autosomal recessive error of metabolism. Abnormal glycogen accumulates in myocytes, hepatocytes, and neurons, causing variably progressive, benign to lethal organ dysfunctions. A naturally occurring orthologue of human GSD IV was described previously in Norwegian forest cats (NFC). Here, we report that while most affected kittens die at or soon after birth, presumably due to hypoglycemia, survivors of the perinatal period appear clinically normal until onset of progressive neuromuscular degeneration at 5 months of age. Molecular investigation of affected cats revealed abnormally spliced GBE1 mRNA products and lack of GBE cross-reactive material in liver and muscle. Affected cats are homozygous for a complex rearrangement of genomic DNA in GBE1, constituted by a 334 bp insertion at the site of a 6.2 kb deletion that extends from intron 11 to intron 12 (g. IVS11+1552_IVS12-1339 del6.2kb ins334 bp), removing exon 12. An allele-specific, PCR-based test demonstrates that the rearrangement segregates with the disease in the GSD IV kindred and is not found in unrelated normal cats. Screening of 402 privately owned NFC revealed 58 carriers and 4 affected cats. The molecular characterization of feline GSD IV will enhance further studies of GSD IV pathophysiology and development of novel therapies in this unique animal model.","dc:creator":"Fyfe JC","dc:date":"2007","dc:title":"A complex rearrangement in GBE1 causes both perinatal hypoglycemic collapse and late-juvenile-onset neuromuscular degeneration in glycogen storage disease type IV of Norwegian forest cats."},"rdfs:label":"GBE1 knockout in Norwegian forest cats "}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:ca9548d9-fd3a-46ea-9ac0-79a77e18a482","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:56834d8f-8ff1-409f-8534-205acb5d155e","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Humans and horses are both at risk for stillbirth/IUFD, weakness in horses correlates with hypotonia and lack of reflexes in humans.  Both humans and horses are at risk for heart failure. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/11817063","type":"dc:BibliographicResource","dc:abstract":"Seven related Quarter Horse foals that died by 7 weeks of age were examined for glycogen branching enzyme (GBE) deficiency. Clinical signs varied from stillbirth, transient flexural limb deformities, seizures, and respiratory or cardiac failure to persistent recumbency. Leukopenia (5 of 5 foals) as well as high serum creatine kinase (CK; 5 of 5), aspartate transaminase (AST; 4 of 4), and gamma glutamyl transferase (GGT; 5 of 5) activities were present in most foals, and intermittent hypoglycemia was present in 2 foals. Gross postmortem lesions were minor, except for pulmonary edema in 2 foals. Muscle, heart, or liver samples from the foals contained abnormal periodic acid Schiff's (PAS)-positive globular or crystalline intracellular inclusions in amounts proportional to the foal's age at death. Accumulation of an unbranched polysaccharide in tissues was suggested by a shift in the iodine absorption spectra of polysaccharide isolated from the liver and muscle of affected foals. Skeletal muscle total polysaccharide concentrations were reduced by 30%, but liver and cardiac muscle glycogen concentrations were normal. Several glycolytic enzyme activities were normal, whereas GBE activity was virtually absent in cardiac and skeletal muscle, as well as in liver and peripheral blood cells of affected foals. GBE activities in peripheral blood cells of dams of affected foals and several of their half-siblings or full siblings were approximately 50% of controls. GBE protein in liver determined by Western blot was markedly reduced to absent in affected foals, and in a half-sibling of an affected foal, it was approximately one-half the amount of normal controls. Pedigree analysis also supported an autosomal recessive mode of inheritance. The affected foals have at least 2,600 half-siblings. Consequently, GBE deficiency may be a common cause of neonatal mortality in Quarter Horses that is obscured by the variety of clinical signs that resemble other equine neonatal diseases.","dc:creator":"Valberg SJ","dc:date":"2001","dc:title":"Glycogen branching enzyme deficiency in quarter horse foals."},"rdfs:label":"GBE1 knockout in quarter horse foals"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:27ec5aa4-6a44-476d-8e4e-8745bb242db6","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:88671a29-bb14-44c9-af7b-a38fc2d0e58f","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Adult onset polyglucosan storage disease is a later onset form of glycogen storage disease due to deficient GBE activity.  The most common pathogenic variant seen in the adult onset condition is Y329S.  The mouse model recapitulates the human phenotype. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26385640","type":"dc:BibliographicResource","dc:abstract":"Glycogen storage disease type IV (GSD IV) is a rare autosomal recessive disorder caused by deficiency of the glycogen-branching enzyme (GBE). The diagnostic hallmark of the disease is the accumulation of a poorly branched form of glycogen known as polyglucosan (PG). The disease is clinically heterogeneous, with variable tissue involvement and age at onset. Complete loss of enzyme activity is lethal in utero or in infancy and affects primarily the muscle and the liver. However, residual enzyme activity as low as 5-20% leads to juvenile or adult onset of a disorder that primarily affects the central and peripheral nervous system and muscles and in the latter is termed adult polyglucosan body disease (APBD). Here, we describe a mouse model of GSD IV that reflects this spectrum of disease. Homologous recombination was used to knock in the most common GBE1 mutation p.Y329S c.986A > C found in APBD patients of Ashkenazi Jewish decent. Mice homozygous for this allele (Gbe1(ys/ys)) exhibit a phenotype similar to APBD, with widespread accumulation of PG. Adult mice exhibit progressive neuromuscular dysfunction and die prematurely. While the onset of symptoms is limited to adult mice, PG accumulates in tissues of newborn mice but is initially absent from the cerebral cortex and heart muscle. Thus, PG is well tolerated in most tissues, but the eventual accumulation in neurons and their axons causes neuropathy that leads to hind limb spasticity and premature death. This mouse model mimics the pathology and pathophysiologic features of human adult-onset branching enzyme deficiency. ","dc:creator":"Orhan Akman H","dc:date":"2015","dc:title":"A novel mouse model that recapitulates adult-onset glycogenosis type 4."},"rdfs:label":"Knock-in of common human disease pathogenic variant"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:27c47257-b003-49ec-b05e-029e894b00ba","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d4339e81-91a7-4812-9459-7370c6689241","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"Rescue of branching enzyme activity","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/8463281","type":"dc:BibliographicResource","dc:abstract":"Functional complementation of the Saccharomyces cerevisiae glycogen branching enzyme deficiency was screened to isolate human cDNAs that encode this enzyme. Human hepatoma cell line HepG2-derived cDNA libraries using the pAB23BXN yeast expression vector yielded four cDNAs capable of complementing the glc3::TRP1 glycogen branching enzyme mutation. Complementation was recognized by an altered iodine-staining trait. This illustrates that interspecies complementation can be used to isolate rare plasmids from libraries by screening if there is sufficient resolution. The human and yeast glycogen branching enzymes have a 67% identical amino acid sequence over a major portion of their length. The human gene is on chromosome 3.","dc:creator":"Thon VJ","dc:date":"1993","dc:title":"Isolation of human glycogen branching enzyme cDNAs by screening complementation in yeast."},"rdfs:label":"Yeast complementation assay"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"cggv:065bf8a1-16bc-4107-a5b8-30c2871f30e5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:0beed8d4-b9dd-4953-b72f-2f7b0d99c7ad","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Affected humans and mice both show the same phenotypes of hydrops, IUFD, stillbirth, abnormal glycogen accumulation in tissues, reduced life expectancy ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21075835","type":"dc:BibliographicResource","dc:abstract":"Glycogen storage disease type IV (GSD-IV) is an autosomal recessive disease caused by a deficiency in glycogen-branching enzyme (GBE1) activity that results in the accumulation of amylopectin-like polysaccharide, which presumably leads to osmotic swelling and cell death. This disease is extremely heterogeneous in terms of tissue involvement, age of onset and clinical manifestation. The most severe fetal form presents as hydrops fetalis; however, its pathogenetic mechanisms are largely unknown. In this study, mice carrying a stop codon mutation (E609X) in the Gbe1 gene were generated using a gene-driven mutagenesis approach. Homozygous mutants (Gbe(-/-) mice) recapitulated the clinical features of hydrops fetalis and the embryonic lethality of the severe fetal form of GSD-IV. However, contrary to conventional expectations, little amylopectin accumulation and no cell degeneration were found in Gbe(-/-) embryonic tissues. Glycogen accumulation was reduced in developing hearts of Gbe(-/-)embryos, and abnormal cardiac development, including hypertrabeculation and noncompaction of the ventricular wall, was observed. Further, Gbe1 ablation led to poor ventricular function in late gestation and ultimately caused heart failure, fetal hydrops and embryonic lethality. We also found that the cell-cycle regulators cyclin D1 and c-Myc were highly expressed in cardiomyocytes and likely contributed to cardiomyocyte proliferation and trabeculation/compaction of the ventricular wall. Our results reveal that early molecular events associated with Gbe1 deficiency contribute to abnormal cardiac development and fetal hydrops in the fetal form of GSD-IV.","dc:creator":"Lee YC","dc:date":"2011","dc:title":"Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV."},"rdfs:label":"Knockout mouse model "}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"cggv:e0784546-4fd3-4868-bdc0-2fcfb099eaee","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:c40660c1-35fb-4ee5-b427-bc6aa40bc0d8","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"Western showing partial rescue of protein expression with addition of stabilizing peptide.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26199317","type":"dc:BibliographicResource","dc:abstract":"Glycogen branching enzyme 1 (GBE1) plays an essential role in glycogen biosynthesis by generating Î±-1,6-glucosidic branches from Î±-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1 structure reveals a conserved amylase core that houses the active centre for the branching reaction and harbours almost all GSDIV and APBD mutations. A non-catalytic binding cleft, proximal to the site of the common APBD mutation p.Y329S, was found to bind the tetra- and hepta-saccharides and may represent a higher-affinity site employed to anchor the complex glycogen substrate for the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the screening of small molecule chaperones, which could become novel therapies for this disease.","dc:creator":"Froese DS","dc:date":"2015","dc:title":"Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design."},"rdfs:label":"Rational peptide design"}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1},{"id":"cggv:a417d6ac-8df5-44a4-b126-69ccd2895de9","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4cbd56ce-ad8e-4c39-8006-e404afbd0f62","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Both affected humans and mice have widespread accumulation of abnormal glycogen in tissues resulting in impaired function and risk for death.   Mice with reduced synthesis survive pregnancy but still show widespread accumulation of abnormal glycogen in tissues and reduced lifespan, similar to humans. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21856731","type":"dc:BibliographicResource","dc:abstract":"Glycogen storage disease type IV (GSD IV) is a rare autosomal recessive disorder caused by deficiency of the glycogen branching enzyme (GBE). The diagnostic feature of the disease is the accumulation of a poorly branched form of glycogen known as polyglucosan (PG). The disease is clinically heterogeneous, with variable tissue involvement and age of disease onset. Absence of enzyme activity is lethal in utero or in infancy affecting primarily muscle and liver. However, residual enzyme activity (5-20%) leads to juvenile or adult onset of a disorder that primarily affects muscle as well as central and peripheral nervous system. Here, we describe two mouse models of GSD IV that reflect this spectrum of disease. Homologous recombination was used to insert flippase recognition target recombination sites around exon 7 of the Gbe1 gene and a phosphoglycerate kinase-Neomycin cassette within intron 7, leading to a reduced synthesis of GBE. Mice bearing this mutation (Gbe1(neo/neo)) exhibit a phenotype similar to juvenile onset GSD IV, with wide spread accumulation of PG. Meanwhile, FLPe-mediated homozygous deletion of exon 7 completely eliminated GBE activity (Gbe1(-/-)), leading to a phenotype of lethal early onset GSD IV, with significant in utero accumulation of PG. Adult mice with residual GBE exhibit progressive neuromuscular dysfunction and die prematurely. Differently from muscle, PG in liver is a degradable source of glucose and readily depleted by fasting, emphasizing that there are structural and regulatory differences in glycogen metabolism among tissues. Both mouse models recapitulate typical histological and physiological features of two human variants of branching enzyme deficiency.","dc:creator":"Akman HO","dc:date":"2011","dc:title":"Generation of a novel mouse model that recapitulates early and adult onset glycogenosis type IV."},"rdfs:label":"Two separate mouse models reflecting spectrum of disease "}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":8201,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"cggv:7c5ca65d-2e07-415e-9239-14b20adee9e3","type":"GeneValidityProposition","disease":"obo:MONDO_0009292","gene":"hgnc:4180","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","dc:description":"Glycogen storage disease type 4 (GSD IV) is a clinically heterogeneous autosomal recessive disease caused by deficiency of the glycogen branching enzyme (GBE) encoded by the GBE1 gene.  Abnormally long chains of glycogen known as polyglucosan bodies accumulate in various tissues of the body resulting in hepatic, cardiac and neurological disease. The severity of disease is correlated with residual activity of the GBE enzyme. Severe prenatal presentations can include fetal akinesia deformation sequence, decreased fetal movements, polyhydramnios, and fetal hydrops. Neonates have profound hypotonia, respiratory distress, and dilated cardiomyopathy, with death typically in early infancy. A historical subtype system used to classify patients along the GSD IV spectrum based on severity and age of onset is no longer favored, as all individuals with GBE deficiency have homozygous or compound heterozygous pathogenic variants in the GBE1 gene.  OMIM currently lists two separate disease entities for GBE1: #232500 for GSD IV and #263570 for adult polyglucosan body disease. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism or inheritance pattern. Therefore, the following disease entities have been lumped into one disease entity, glycogen storage disease due to glycogen branching enzyme deficiency (MONDO: 0009292)\n\nWe have curated 26 variants in GBE1 (missense, nonsense, frameshift, large deletion) reported in 17 probands across 7 publications (PMIDs: 8613547, 15452297, 15019703, 17662246, 15520786, 16278887, 12913206). More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity is known to be loss of function. The gene-disease association is also supported by experimental evidence showing reduced GBE expression and activity in patient cells, reduced GBE activity in COS-7 cells transfected with specific GBE1 variants, multiple animal models including three separate mouse models that mimic varying disease severities with GBE1 gene alterations, and finally partial rescue of activity using a peptide designed to increase protein stability  (PMIDs: 8613547, 9851430, 15452297, 11817063, 17257876, 21075835, 21856731, 26385640, 26199317). \n\nIn summary, the GBE1 gene is definitively associated with autosomal recessive GBE IV.  This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Prenatal GCEP on the meeting date August 23, 2023 (SOP Version 9). \n\nThe GBE1 gene is definitively associated with autosomal recessive GBE IV.  This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":{"id":"cggv:3f01d412-0f6d-4a0f-88db-b55b2af4a0a2"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}